GLP-1 medication for psoriatic arthritis outcomes
Part of Bones, joints & muscles, Skin clinical trials.
This study tests if adding a GLP-1 medication (a type of drug that helps with weight and blood sugar) to your usual psoriatic arthritis treatment can improve your joint and skin symptoms. It is for people with psoriatic arthritis who have not yet achieved good control of their disease and have a higher body weight.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have psoriatic arthritis (diagnosed by a doctor)
- Your BMI is 30 or higher
- Your psoriatic arthritis is not well-controlled (not in a state called 'minimal disease activity')
- You have never taken a GLP-1 medication (like Ozempic or Wegovy) before
- You are willing to start a GLP-1 medication as part of this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a weight-loss medication (tirzepatide) to a biologic (ixekizumab) helps people with psoriatic arthritis and overweight or obesity. You will need to have biopsies of joint tissue and fat to see how the treatment affects inflammation.
This trial tests if a GLP-1 receptor agonist (a type of diabetes medication) can help treat psoriatic arthritis in people who are overweight but do not have diabetes. You might join if you have psoriatic arthritis, a high BMI, and you are of Chinese descent.
This study tests a drug that helps with weight loss and blood sugar (called a GLP-1 receptor agonist) combined with a special diet to see if it can improve symptoms in people with mild Crohn's disease. You may join if you have Crohn's, a BMI of 27 or higher, and are already on a stable dose of a TNF blocker.
This study looks at whether GLP-1 analog medications (a type of diabetes drug) can lower the risk of developing osteoarthritis in people with type 2 diabetes. It compares them to another diabetes drug class, SGLT2 inhibitors.
This trial tests if semaglutide, a medicine used for diabetes and weight loss, can help people with both psoriasis and obesity. You may qualify if you have moderate to severe psoriasis, a high body weight, and are of Chinese descent.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
Hear when a new Psoriatic Arthritis (PsA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.